Catalog No.S1894 Synonyms: CGP-48933
Molecular Weight(MW): 435.52
Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Purity & Quality Control
Choose Selective RAAS Inhibitors
|Description||Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.|
Valsartan dose-dependently inhibits the vasoconstriction induced by angiotensin II and lowers blood pressure in renin-dependent models of hypertension. Valsartan is at least as effective as ACE inhibitors, diuretics, beta-blockers and calcium antagonists. 
|In vivo||Valsartan results in improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels in mice fed a Western diet. Valsartan treatment also blocks Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1. Valsartan enhances mitochondrial function and prevents Western diet-induced decreases in glucose-stimulated insulin secretion in the pancreatic islets of mice. Valsartan treatment blocks or attenuates Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R in isolated adipocytes.  Valsartan significantly increases insulin-mediated 2-[3H]deoxy-d-glucose (2-[3H]DG) uptake into skeletal muscle and attenuates the increase in plasma glucose concentration after a glucose load and plasma concentrations of glucose and insulin. Valsartan treatment exaggerates the insulin-induced phosphorylation of IRS-1, the association of IRS-1 with the p85 regulatory subunit of phosphoinositide 3 kinase (PI 3-K), PI 3-K activity, and translocation of GLUT4 to the plasma membrane. Valsartan also reduces tumor necrosis factor-alpha (TNF-alpha) expression and superoxide production in skeletal muscle of KK-Ay mice. |
|In vitro||DMSO||87 mg/mL (199.76 mM)|
|Ethanol||87 mg/mL (199.76 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02662894||Not yet recruiting||Hypertension|Dyslipidemia||EMS||October 2019||Phase 3|
|NCT03738878||Not yet recruiting||Hypertension||Vanderbilt University Medical Center||November 15 2018||Phase 4|
|NCT03594825||Not yet recruiting||Hypertension;Nephropathy||Fifth Affiliated Hospital Sun Yat-Sen University|Third Affiliated Hospital Sun Yat-Sen University||November 2018||Phase 4|
|NCT03315832||Not yet recruiting||Aortic Valve Stenosis|Valsartan|Angiotensin Receptor Antagonists|Transcatheter Aortic Valve Replacement|Heart Valve Prosthesis Implantation|Hypertrophy Left Ventricular||University Hospital Limoges||October 2 2018||Phase 2|Phase 3|
|NCT03476616||Not yet recruiting||Hypertension|Obesity||Hippocration General Hospital||September 1 2018||Phase 4|
|NCT03541109||Not yet recruiting||Ischemic Heart Disease|Acute Coronary Syndrome|Revascularization||Isfahan University of Medical Sciences|Tehran University of Medical Sciences||August 2018||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.